Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
COPD
Questions discussed in this category
Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?
1 Answer available
What is your threshold to start triple therapy in mild to moderate asthma/COPD overlap with minimal functional limitation?
1 Answer available
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Does active smoking status influence this decision?
2 Answers available
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
2 Answers available
Are the results of the BOREAS trial generalizable to non-white populations?
The cohort in the study was predominantly white. Do these results highlight significant disparities in COPD care?
2 Answers available
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
If so, would this be a consideration in all patients regardless of active smoking status? FeNO in active smokers has been questioned, could this have ...
2 Answers available
How do you choose between azithromycin and roflumilast in the management of a patient with severe COPD who remains symptomatic with frequent exacerbations despite maximal dose LABA/LAMA/ICS with demonstrated compliance and proper inhaler technique?
1 Answer available
Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?
1 Answer available
Is there a role for biologic therapies in asthma-COPD overlap syndrome with evidence of type 2 inflammation?
2 Answers available
20180
15058
17735
17736
17737
17738
14202
14479
12502
Papers discussed in this category
American journal of respiratory and critical care medicine, 2023 Aug 15
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Related Topics
Pulmonology
Obstructive Lung Disease
Journal Club ft. NEJM publications
Asthma
Internal Medicine
Allergy & Immunology
Rheumatology
Psoriatic arthritis
General Rheumatology
Pharmacology